ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CAT Catco Reinsurance Opportunities Fund Limited

24.00
0.00 (0.00%)
16 Aug 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Catco Reinsurance Opportunities Fund Limited LSE:CAT London Ordinary Share BMG1961Q3242 ORD USD0.00013716 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 24.00 13.00 35.00 24.00 24.00 24.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Unit Inv Tr, Closed-end Mgmt 6.33M 5.44M 3.6440 6.59 35.84M

CAT extends DRC offer again

28/03/2002 7:00am

UK Regulatory


RNS Number:7407T
Cambridge Antibody Tech Group PLC
28 March 2002

02/CAT/15

Not for release in Australia, Japan and the Republic of Ireland

FOR IMMEDIATE RELEASE

22.00 GMT 17.00 EST Wednesday 27 March 2002

For Further Information Contact:

Cambridge Antibody Technology              Weber Shandwick Square Mile (Europe)

Tel: +44 (0) 1763 263 233                  Tel: +44 (0) 20 7950 2800

John Aston, Finance Director               Kevin Smith

Rowena Gardner, Head of Corporate          Graham Herring
Communications
                                           BMC Communications/The Trout Group (USA)

                                           Tel: 001 212 477 9007

                                           Brad Miles, ext 17 (media)

                                           Brandon Lewis, ext.15 (investors)



CAMBRIDGE ANTIBODY TECHNOLOGY FURTHER EXTENDS OFFER FOR DRUG ROYALTY CORPORATION
                                TO 26 APRIL 2002

Melbourn, UK and Toronto, Canada... Cambridge Antibody Technology Group plc
("CAT") (LSE: CAT; NASDAQ: CATG) announced today that it has extended its offer,
through its wholly-owned subsidiary 3982904 Canada Inc., to acquire all of the
outstanding common shares of Drug Royalty Corporation Inc. ("DRC") (TSE: DRI) to
9.00 pm (EST) on Friday 26 April 2002. A formal notice of the extension of the
offer will be mailed as soon as is practicable.

                                -ENDS-


                      This information is provided by RNS
            The company news service from the London Stock Exchange

1 Year Catco Reinsurance Opport... Chart

1 Year Catco Reinsurance Opport... Chart

1 Month Catco Reinsurance Opport... Chart

1 Month Catco Reinsurance Opport... Chart

Your Recent History

Delayed Upgrade Clock